Boundedness for commutators of fractional integrals on Herz-Morrey spaces with variable exponent

In this paper, some boundedness for commutators of fractional integrals are obtained on Herz-Morrey spaces with variable exponent applying some properties of varible exponent and \BMO function.Comment: In 2013, it is accepted by Kyoto Journal of Mathematics. And there are 10 page

Some notes on commutators of the fractional maximal function on variable Lebesgue spaces

Let $0<\alpha<n$ and $M_{\alpha}$ be the fractional maximal function. The nonlinear commutator of $M_{\alpha}$ and a locally integrable function $b$ is given by $[b,M_{\alpha}](f)=bM_{\alpha}(f)-M_{\alpha}(bf)$. In this paper, we mainly give some necessary and sufficient conditions for the boundedness of $[b,M_{\alpha}]$ on variable Lebesgue spaces when $b$ belongs to Lipschitz or BMO(\rn) spaces, by which some new characterizations for certain subclasses of Lipschitz and BMO(\rn) spaces are obtained.Comment: 20 page

Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies

Background and objectivesAn increasing number of patients with antithrombotic therapies are undergoing endoscopic retrograde cholangiopancreatography (ERCP). Interruption of antithrombotic therapies may be associated with a higher risk of symptomatic thromboembolic (TE) events. We aimed to investigate the risk of symptomatic TE events among patients undergoing ERCP.MethodsA retrospective cohort study on patients at risk for symptomatic TE events who had undergone ERCP from January 2016 to October 2023 was conducted. A total of 2,482 patients who had undergone ERCP were included in this study. We compared the risk of symptomatic TE events within 30 days after ERCP between the group treated with antithrombotic agent and the group not treated with antithrombotic agent using multivariate regression analysis adjusted for covariates.ResultsA total of 15 patients (0.60%, 15/2,482) developed symptomatic TE events within 30 days after ERCP. The symptomatic TE event rate in subjects on any antithrombotic drug was 1.46% with an odds ratio (OR) of 5.267 (n = 689, 95% CI 1.79–15.46, p = 0.002), compared with those not treated with antithrombotic drugs (n = 1,793). The symptomatic TE event rate in subjects on temporary interruption of antithrombotic drugs was 1.48% with an OR of 5.36 (n = 677, 95% CI 1.83–15.74, p = 0.002), compared with those not treated with antithrombotic drugs (n = 1,793). Multivariate regression analysis indicated that patients with high-risk conditions had a significantly higher risk of post-ERCP symptomatic TE events (adjusted OR 11.73, 95% CI 2.23–61.70).ConclusionInterruption of antithrombotic drugs is associated with higher post-ERCP symptomatic TE events, particularly in high-risk conditions